R. L. Siegel and K. D. Miller, Cancer statistics, vol.69, pp.7-34, 2019.

R. L. Pearlman, M. K. Montes-de-oca, H. C. Pal, and A. F. , Potential therapeutic targets of epithelial-mesenchymal transition in melanoma, Cancer Lett, vol.391, pp.125-140, 2017.

J. Larkin, P. A. Ascierto, B. Dreno, V. Atkinson, G. Liszkay et al., Combined vemurafenib and cobimetinib in BRAF-mutated melanoma, N Engl J Med, vol.371, pp.1867-1876, 2014.

J. Larkin, F. S. Hodi, and J. D. Wolchok, Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, N Engl J Med, vol.373, pp.1270-1271, 2015.

K. T. Flaherty, I. Puzanov, K. B. Kim, A. Ribas, G. A. Mcarthur et al., Inhibition of mutated, activated BRAF in metastatic melanoma, N Engl J Med, vol.363, pp.809-819, 2010.

D. B. Johnson, R. J. Sullivan, P. A. Ott, M. S. Carlino, N. I. Khushalani et al., Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders, JAMA Oncol, vol.2, pp.234-240, 2016.

E. Fonkem, E. J. Uhlmann, S. R. Floyd, A. Mahadevan, E. Kasper et al., Melanoma brain metastasis: overview of current management and emerging targeted therapies, Expert Rev Neurother, vol.12, pp.1207-1215, 2012.

N. Khan, M. K. Khan, A. Almasan, A. D. Singh, and R. Macklis, The evolving role of radiation therapy in the management of malignant melanoma, Int J Radiat Oncol Biol Phys, vol.80, pp.645-654, 2011.

V. J. Hearing, The melanosome: the perfect model for cellular responses to the environment, Pigment Cell Res, vol.13, issue.8, pp.23-34, 2000.

M. Cichorek, M. Wachulska, A. Stasiewicz, and A. Tyminska, Skin melanocytes: biology and development, Postepy Dermatol Alergol, vol.30, pp.30-41, 2013.

C. Delevoye, Melanin transfer: the keratinocytes are more than gluttons, J Invest Dermatol, vol.134, pp.877-879, 2014.

S. P. Svensson, S. Lindgren, W. Powell, and H. Green, Melanin inhibits cytotoxic effects of doxorubicin and daunorubicin in MOLT 4 cells, Pigment Cell Res, vol.16, pp.351-354, 2003.

E. Dadachova and A. Casadevall, Melanin as a potential target for radionuclide therapy of metastatic melanoma, Future Oncol, vol.1, pp.541-549, 2005.

F. Cachin, E. Miot-noirault, B. Gillet, V. Isnardi, B. Labeille et al., )I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial, J Nucl Med, vol.55, issue.123, pp.15-22, 2014.

A. Norain and E. Dadachova, Targeted radionuclide therapy of melanoma, Semin Nucl Med, vol.46, pp.250-259, 2016.

M. Klein, M. Lotem, T. Peretz, S. T. Zwas, S. Mizrachi et al., Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma, J Skin Cancer, 2013.

Y. Miao, T. Shelton, and Q. Tp, Therapeutic efficacy of a 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model, Cancer Biother Radiopharm, vol.22, pp.333-341, 2007.

N. Moins, D. 'incan, M. Bonafous, J. Bacin, F. Labarre et al., 123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging, Eur J Nucl Med Mol Imaging, vol.29, pp.1478-1484, 2002.

W. Mier, C. Kratochwil, J. C. Hassel, F. L. Giesel, B. Beijer et al., Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52, J Nucl Med, vol.55, pp.9-14, 2014.

M. Bonnet, F. Mishellany, J. Papon, A. Cayre, F. Penault-llorca et al., Anti-melanoma efficacy of internal radionuclide therapy in relation to melanin target distribution, Pigment Cell Melanoma Res, vol.23, pp.1-11, 2010.

M. Bonnet-duquennoy, J. Papon, F. Mishellany, P. Labarre, J. L. Guerquin-kern et al., Targeted radionuclide therapy of melanoma: anti-tumoural efficacy studies of a new 131I labelled potential agent, Int J Cancer, vol.125, pp.708-716, 2009.

J. M. Chezal, J. Papon, P. Labarre, C. Lartigue, M. J. Galmier et al., Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma, J Med Chem, vol.51, pp.3133-3144, 2008.

F. Degoul, M. Borel, N. Jacquemot, S. Besse, Y. Communal et al., In vivo efficacy of melanoma internal radionuclide therapy with a 131I-labelled melanin-targeting heteroarylcarboxamide molecule, Int J Cancer, vol.133, pp.1042-1053, 2013.
URL : https://hal.archives-ouvertes.fr/in2p3-00926259

C. Viallard, J. M. Chezal, F. Mishellany, I. Ranchon-cole, B. Pereira et al., Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy, Oncotarget, vol.7, pp.12927-12936, 2016.

N. Sundahl, F. Duprez, P. Ost, and W. De-neve, Effects of radiation on the metastatic process, Mol Med, vol.24, p.16, 2018.

B. Rioux, J. Rouanet, H. Akil, S. Besse, E. Debiton et al., Determination of eumelanin and pheomelanin in melanomas using solid-phase extraction and high performance liquid chromatography-diode array detection (HPLC-DAD) analysis, J Chromatogr B Analyt Technol Biomed Life Sci, vol.1113, pp.60-68, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02346260

K. Buch, T. Peters, T. Nawroth, M. Sanger, H. Schmidberger et al., Determination of cell survival after irradiation via clonogenic assay versus multiple MTT Assay-a comparative study, Radiat Oncol, vol.7, issue.1, 2012.

H. Akil, A. Abbaci, F. Lalloue, B. Bessette, L. M. Costes et al., IL22/IL-22R pathway induces cell survival in human glioblastoma cells, PLoS One, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01704496

H. E. Seberg, E. Van-otterloo, and C. Ra, Beyond MITF: Multiple transcription factors directly regulate the cellular phenotype in melanocytes and melanoma, Pigment Cell Melanoma Res, vol.30, pp.454-466, 2017.

C. Viallard, Y. Perrot, Z. Boudhraa, E. Jouberton, E. Miot-noirault et al., )I]ICF01012 dosimetry allow adapted internal targeted radiotherapy in preclinical melanoma models, Eur J Dermatol, vol.25, issue.1, pp.29-35, 2015.

G. Botti, G. Scognamiglio, L. Marra, F. Collina, D. Bonito et al., SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression, Virchows Arch, vol.465, pp.331-338, 2014.

J. Caramel, E. Papadogeorgakis, L. Hill, G. J. Browne, G. Richard et al., A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma, Cancer Cell, vol.24, pp.466-480, 2013.

C. Wellbrock, S. Rana, H. Paterson, H. Pickersgill, T. Brummelkamp et al., Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF, PLoS One, 2008.